Tesamorelin is a synthetic peptide analogof growth hormone-releasing hormone (GHRH), developed to stimulate the production and release of endogenous growth hormone (GH) from the pituitary gland. It consists of a 44-amino acid sequence that closely resembles natural GHRH but is modified to enhance stability and biological activity. Tesamorelin has gained attention in clinical and preclinical research for its targeted effects on the GH/IGF-1 axis, particularly in metabolic, endocrine, and age-related studies. Its unique design allows for more efficient receptor binding while retaining a biochemical structure compatible with physiological pathways.